BioNTech to Acquire CureVac for $1.25 Billion
by 
BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities. The strategic transaction will combine complementary mRNA technologies in design, delivery formulations, and manufacturing to accelerate development of transformative cancer treatments and establish new standards of care. The deal has secured support from shareholders representing 50.08% of CureVac shares and is expected to close in 2025, marking a key milestone in BioNTech’s oncology strategy focused on pan-tumor programs and bispecific antibody candidates.
“This transaction is another building block in BioNTechView company profile’s oncologySearch disease strategy and an investment in the future of cancerSearch disease medicine,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years.”
Dr. Alexander Zehnder, CEO of CureVacView company profile, emphasized the transformative potential of combining the companies’ capabilities: “This transaction aims at combining complementary scientific capabilities, proprietary technologies, and manufacturing expertise in the mRNASearch drug field under one roof.”
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/
